Marriott (MAR) Declares $0.41 Quarterly Dividend; 1.4% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- SanDisk shares fall on election and chip sector pressure
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Marriott International (MAR) PT Lowered to $123 at Morgan Stanley
November 8, 2018 8:10 AM ESTMorgan Stanley analyst Thomas Allen lowered the price target on Marriott International (NASDAQ: MAR) to $123.00 (from $138.00) while maintaining a Equalweight rating.
... MoreMarriott International (MAR) PT Lowered to $123 at Deutsche Bank
November 7, 2018 5:22 AM ESTDeutsche Bank analyst Carlo Santarelli lowered the price target on Marriott International (NASDAQ: MAR) to $123.00 (from $136.00) while maintaining a Hold rating.
... MoreMarriott International (MAR) PT Lowered to $147 at Longbow Research
November 6, 2018 11:53 AM ESTLongbow Research analyst Alton Stump lowered the price target on Marriott International (NASDAQ: MAR) to $147.00 (from $156.00) while maintaining a Buy rating.
The cut following the EPS beat but disappointing Q3 RevPar.
... MorePre-Open Movers 11/06: (VCEL) (ELF) (MYL) Higher; (ONCS) (FTDR) (RL) Lower (more...)
November 6, 2018 9:24 AM ESTToday's Pre-Open Stock Movers
OncoSec Medical Incorporated (NASDAQ: ONCS) 56.9% LOWER; reported preliminary data from KEYNOTE-695, a global, multicenter Phase 2b, open-label trial of intratumoral delivery of TAVO (tavokinogene telseplasmid / IL-12) with intravenous KEYTRUDA® (pembrolizumab) in patients with unresectable, advanced melanoma. Eligible patients had refractory, locally advanced or metastatic disease defined as unresectable Stage... More



